CDK4 Antibody (DA133)

Description

Well-differentiated liposarcoma is a malignant, non-metastasizing tumor that can present with similar histological characteristics as benign lipoma lesions and has a higher recurrence rate. The CDK4 protein is frequently overexpressed in well-differentiated liposarcoma due to gene amplification of the 12q13-15 chromosomal region that harbors the CDK4 gene, but amplification and subsequent overexpression is rarely observed in lipomas. Due to CDK4 protein expression differences between these lesions, anti-CDK4 antibody can be used in an immunohistochemistry panel as an aid in the differential diagnosis between well-differentiated liposarcoma and lipoma.1,2,3 — Références — 1. Thway K, et al. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors. Am J Surg Pathol. 2012; 36(3):462-9. 2. Aleixo PB, et al. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. J Clin Pathol. 2009; 62(12):1127-35. 3. Binh MBN, et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: A comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol. 2005; 29(10):1340-7.

Caractéristiques

Type

Recombinant monoclonal rabbit antibody

Clone

DA133

Isotype

Rabbit

Réactivité

Synthetic peptide of human CDK4

Localisation

Cytoplasm/Nucleus

Usage prévu

IHC (FFPE)